Abstract
Both brain and bone imaging are often required in evaluating patients with suspected metastatic disease. This usually necessitates a delay of one to two days between the studies since 99mTc is routinely used in both procedures. This article describes a possible method of eliminating this time delay by utilizing 99mTc-diphosphonate as a sequential brain- and bone-imaging radiopharmaceutical. The results indicate that detection of intracranial lesions with 99mTc-diphosphonate compares favorably with pertechnetate cerebral imaging in the studies presented and it may be a suitable agent for sequential brain and bone imaging.